Biogen Inc.(BIIB)

Sector:

Healthcare

Description:

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Current Price

$300.20

RSI

45.82

Market Capitalization:

39.1B

Beta:

0.167

Volume:

817,147

Analyst Target Price:

$ 279.03

Economiic Fair Price:


February 02, 2023
July 20, 2022
Q2
N/A
N/A
N/A
N/A
N/A
2.6B
7.6B
13.89
19.40 %
72.36
0.137

-8.64 %
9.41 %
26.99 %
-6.70 %
118.09 %
-39.61 %

$ 11B
-18.32 %
$ 13.4B
-6.49 %
$ 14.4B
6.88 %
$ 13.5B
9.61 %
$ 12.3B
7.21 %
$ 11.4B

$ 3.3B
-9.05 %
$ 3.7B
-42.61 %
$ 6.4B
20.89 %
$ 5.3B
104.84 %
$ 2.6B
-31.79 %
$ 3.8B

$ 1.7B
-65.42 %
$ 5B
-29.17 %
$ 7.1B
20.79 %
$ 5.9B
15.03 %
$ 5.1B
3.97 %
$ 4.9B

News

Press Releases

Notable Dates